Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00611741 · ClinicalTrials.gov registry record · Phase 1
The Effect of Plasma Osmolality on Brain Glutamate
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00611741 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 30 participants.
The verdict
NCT00611741, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is designed to test the hypothesis that plasma osmolality is linked with cortical glutamate concentrations in the brain. It also investigates whether the glutamate response in schizophrenia is enhanced compared to healthy controls.
Interventions
- DRUG furosemide, Na supplements
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2007-03 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00611741
The ClinicalTrials.gov registry entry for NCT00611741 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which furosemide, Na supplements is the first listed.
NCT00611741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00611741 about?
NCT00611741 is a clinical study titled "The Effect of Plasma Osmolality on Brain Glutamate". This study is designed to test the hypothesis that plasma osmolality is linked with cortical glutamate concentrations in the brain. It also investigates whether the glutamate response in schizophrenia is enhanced compared to healthy controls.
What is the current status of trial NCT00611741?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2007-03. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00611741?
The interventions under investigation include: furosemide, Na supplements (DRUG).
Who is sponsoring clinical trial NCT00611741?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.